BMO Hosts Third Annual Metabolic Health Summit on the Future of the GLP-1+ Market

Healthcare industry experts and leaders to convene March 24 at the 2026 BMO Metabolic Health Summit (formerly the Obesity Summit) to examine outlook and trends in metabolic disease and drug therapies

NEW YORK, March 10, 2026 /CNW/ - BMO Capital Markets will host its 2026 Metabolic Health Summit, the next evolution of its former Obesity Summit in New York on March 24^th, 2026. This summit reflects the rapid advancement of metabolic, cardiovascular, and cardiometabolic science--including the broad and growing impact of GLP-1–based therapies across obesity, diabetes, heart failure, and renal health. The summit will convene industry-leading BioPharma innovators, experts, and investors for a full day of thought leadership panels, fireside conversations with corporate management, and small-group or one-on-one meetings exploring the future of metabolic health innovation.

What:	BMO Metabolic Health Summit 2026
	Hosted & moderated by Evan Seigerman,
	Head of Healthcare Research, BMO Capital Markets
Who:	Industry leading BioPharma innovators, experts and investors
When:	Tuesday, March 24, 2026 • 7:30 a.m. – 4:30 p.m. ET
Where:	Westin Grand Central – 3rd Floor
	212 E 42nd St, New York, NY 10017
	In-person only (no webcast)

The BMO Metabolic Health Summit will deliver thought leadership and corporate management perspectives in a variety of formats such as fireside chats, expert panels and presentations, including:

• Discussions hosted by BMO analysts with leading life sciences companies, including Aardvark Therapeutics, Amgen, Ascletis Pharma, Biomea Fusion, Corbus Pharmaceuticals, Eli Lilly & Co., Novo Nordisk, Pfizer, and Structure Therapeutics
• Obesity 103 with Katherine Saunders, MD, Obesity Physician & Co-Founder, FlyteHealth
• A discussion on the state of Obesity Medicine in 2026 with Dr. Louis J. Aronne, M.D., Sanford I. Weill Professor of Metabolic Research, Weill Cornell Medical College
• Panels on care delivery, emerging technologies, coverage and access ft. WeightWatchers, Metaphore Biotechnologies, Nuevocor Therapeutics, ProCare Rx, Ro Health, Superluminal Medicines, and Virta Health
• Insights from patients on GLP-1+ therapy

For more information or to request an interview with one of BMO's equity research analysts, please contact BMO Media Relations using the contact details below. Note: There may be restrictions for media on access to some presentations.

Event Resources: Agenda, Participating Companies

About BMO Financial Group 

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of January 31, 2026. Serving clients for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to approximately 13 million clients across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and stronger communities.   

SOURCE BMO Financial Group

Media contact: Kelly Hechler, Toronto, [email protected], [phone]